Gilead Sciences GILD Tecartus — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's tecartus — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's tecartus — total revenues?
- Gilead Sciences (GILD) reported tecartus — total revenues of $75M in Q1 2026.
- How has Gilead Sciences's tecartus — total revenues changed year-over-year?
- Gilead Sciences's tecartus — total revenues decreased by 3.8% year-over-year, from $78M to $75M.
- What is the long-term trend for Gilead Sciences's tecartus — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's tecartus — total revenues has grown at a 18.2% compound annual growth rate (CAGR), from $176M to $343M.
- What does tecartus — total revenues mean?
- The total amount of money earned from sales of the Tecartus cell therapy product.
- How do you interpret tecartus — total revenues?
- An increase indicates growing market penetration and clinical adoption of the therapy, while a decrease may signal increased competition, patent expirations, or shifts in treatment guidelines.
- How does tecartus — total revenues compare across companies?
- Comparable to revenue metrics for specialized oncology or rare disease therapies at other biopharmaceutical companies, often evaluated against market share in specific cancer indications.